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Objectives: Although there is increased awareness of patient and public involvement (PPI) among health technology assessment (HTA) organizations, evaluations of PPI initiatives
are relatively scarce. Our objective as members of Health Technology Assessment International’s (HTAi’s) Patient and Citizen Involvement Group (PCIG) was to advance
understanding of the range of evaluation strategies adopted by HTA organizations and their potential usefulness.
Methods: In March 2016, a survey was sent to fifty-four HTA organizations through the International Network of Agencies for Health Technology Assessment (INAHTA) and contacts
of members of HTAi’s PCIG. Respondents were asked about their organizational structure; how patients and members of the public are involved; whether and how PPI initiatives
have been evaluated, and, if so, which facilitators and challenges to evaluation were found and how results were used and disseminated.
Results: Fifteen (n = 15) programs from twelve countries responded (response rate 27.8 percent) that involved patients (14/15) and members of the public (10/15) in HTA
activities. Seven programs evaluated their PPI activities, including participant satisfaction (5/7), process (5/7) and impact evaluations (4/7). Evaluation results were used to
improve PPI activities, identify education and training needs, and direct strategic priorities. Facilitators and challenges revolved around the need for stakeholder buy-in, sufficient
resources, senior leadership, and including patients in evaluations.
Conclusions: A small but diverse set of HTA organizations evaluate their PPI activities using a range of strategies that reflect the range of rationales and approaches to PPI in HTA. It
will be important for HTA organizations to draw on evaluation theories and methods.
Keywords: Patient involvement, Public involvement, Evaluation
Increasingly, health technology assessment (HTA) organiza-
tions are involving patients, members of the public, or both, in
some aspect of their HTA processes (1–8). Patient and public
involvement (PPI) includes a range of strategies used across the
HTA and decision-making process with the goal of informing
(e.g., information broadcasts, Web site), consulting (e.g., sur-
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vey, focus group) or actively engaging with patients or mem-
bers of the public for the purpose of research, policy, or pro-
gram development (e.g., citizen jury, advisory committee par-
ticipation) (9–12).
Although there may be increased awareness of PPI amongst
HTA organizations, published evaluations of PPI initiatives are
still relatively scarce (12). Where such evaluations do exist,
more tend to focus on evaluating the impact of PPI (1;2;4),
as opposed to the process (13), and tend to be circumscribed
to a single HTA topic, or program (1;2;4;14). In two surveys
of member agencies of the International Network of Agencies
for Health Technology Assessment (INAHTA) in 2005 (15) and
2010 (16), eight and six agencies, respectively, reported having
evaluated their consumer involvement activities, although the
definition for evaluation was broad and included limited activ-
ities such as noting the type of input and number of submis-
sions received, and the influence of input on HTA quality and
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relevance. The Patient and Citizen Involvement Group of
Health Technology Assessment International (HTAi) leads an
initiative to document and share good practice examples of PPI
in HTA (17). This initiative has helped document a variety of
strategies used across eleven international HTA programs, and
share perceptions of best practice. While it is possible that some
descriptions are out of date, only three of the eleven programs
who contributed good practice examples also reported evaluat-
ing their strategies or measuring their impact.
The lack of published evaluations of PPI initiatives in HTA
limits the refinement of theory to guide best practices. Who
best to include in HTA, how best to recruit, consult, involve or
engage them, and with what support remain somewhat unan-
swered questions (4;18–20). We conducted a survey of inter-
national HTA agencies to address the need to better understand
whether and how HTA programs are evaluating their PPI strate-
gies and with what results, as well as perceived facilitators and
barriers to evaluation.
METHODS
A questionnaire (Supplemental File 1) was developed and in-
formed by studies on the impact of PPI on health and social care
research, and their stakeholders (18;21;22). Questions sought
information on: (i) HTA organizations, including the structure
and jurisdiction; (ii) how patients and members of the public are
involved in HTA processes (e.g., topic identification, apprais-
ing evidence) and HTA decision making (e.g., participation on
committees, making recommendations); (iii) whether and how
PPI strategies have been evaluated, and if so how the informa-
tion was used and disseminated; (iv) lessons learned including
facilitators and challenges to PPI evaluations; and (v) specific
details about completed evaluations including the objectives,
methods, and results.
In March 2016, we sent email invitations: (i) through the
INAHTA Secretariat to its 52 members; (ii) to contacts within
the eleven HTA organizations who responded to the HTAi ini-
tiative to collect good practice examples of PPI in HTA (one of
which is not an INAHTA member); and, (iii) to seven personal
contacts of the authors (one of which was not contacted through
either of the two prior methods). In total, we directly invited
fifty-four individual organizations to participate, and addition-
ally pursued snowball sampling by encouraging participants to
forward the questionnaire to their contacts who might be doing
this type of work.
The invitation introduced the purpose of our survey, re-
quested that only one questionnaire per organization was com-
pleted, and requested the recipient to forward the questionnaire
to “the appropriate person” within their organization for com-
pletion. The questionnaire took approximately 20 to 30 minutes
to complete, and was hosted on the online SurveyMonkey plat-
form (www.surveymonkey.com). Before distribution, a draft
questionnaire was pilot tested by a staff member at the Cana-
dian Agency for Drugs and Technologies in Health (CADTH)
who was not involved in the development of the questionnaire,
and the resultant feedback was used to revise the questionnaire.
Potential respondents were given the option to request a
structured telephone interview instead of completing the on-
line questionnaire. During the two interviews that took place, a
study investigator covered the same content as was in the on-
line questionnaire, took detailed notes and developed a written
account of the participant’s responses, which became part of
the same dataset as responses submitted online. Similarly, we
asked online participants for permission to contact them to clar-
ify any submitted responses, if necessary, and four participants
were contacted for follow up.
Two investigators (J.P. and A.H.) reviewed all responses for
clarity, completeness and analysis. Frequencies of responses
were calculated for close-ended questions, and responses to
open-ended questions were summarized narratively.
This survey did not require formal approval from a research
ethics board as the focus was on HTA organization procedures
and not the individuals completing the questionnaire (23), al-
though we followed ethical practices for survey research. We
provided sufficient information about the purpose and process
of the survey to enable an informed decision to participate or
not, indicated that any information provided would be used in
a peer-reviewed journal publication such that submission of a
completed questionnaire implied informed consent for that pur-
pose, and explicitly informed participants that their information
would be shared publicly and their organization and related in-
formation would be identifiable.
RESULTS
We received fifteen completed questionnaires (15/54 = 27.8
percent response rate), among which twelve countries were
represented. Two organizations each were from the United
Kingdom (National Institute for Health and Care Excellence
[NICE], Scottish Medicines Consortium (SMC]), Netherlands
(Zorginstituut Nederland [ZiNL], Netherlands Organization
for Health and Research Development [ZonMw]), and Tai-
wan (Center for Drug Evaluation [CDE], Clinical Effec-
tiveness Group). The additional respondents were based in
Canada (Canadian Agency for Drugs and Technology in Health
[CADTH]), Columbia (Instituto de Evaluación Tecnológica en
Salud [IETS]), France (Haute Autorité de Santé [HAS]), Ger-
many (Gemeinsamer Bundesausschuss [G-BA]), Italy (Agen-
zia Nazionale per i servizi sanitari Regionali [AGENAS]),
Luxembourg (Cellule d’expertise médicale [CEM]), Poland
(Agency for Health Technology Assessment in Poland [AH-
TAPol]), Romania (Center of health care quality and control),
and Sweden (Swedish Agency for health technology assess-
ment and assessment of social services [SBU]). Table 1 de-
scribes participating HTA organizations, their stated reasons
for involving patients and members of the public in HTA, and
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Table 1. Description of Participating HTA Organizations
HTA organization involves
Organization,
country
HTA organization
structure, level
Stated reasons for patient and
public initiatives Patients Members of the public
Type of evaluations conducted;
frequency of evaluation
CADTH, Canada Quasi-
governmental,
pan-Canadian
• To promote fairness and inclusion
of a range of stakeholders
• To enhance patient or public
support of decisions
• To help ensure decisions reflect
patient and public values
• To enhance patient and public
understanding of HTA
• Participation on a working
group or committee
• Refining scope
• Identifying clinical
outcomes
• Data collection
• Reviewing reports
• Disseminating results
• Participation on a
working group or
committee
• Refining scope
• Reviewing reports
• Process, impact
•> 3 year interval
IETS, Colombia Quasi-
governmental,
national
• To promote fairness and inclusion
of a range of stakeholders
• To enhance patient or public
support of decisions
• To help ensure decisions reflect
patient and public values
• Participation on a working
group or committee
• Refining the scope of an
assessment
• Identifying clinical
outcomes
• Reviewing protocol
• Making recommendations
• Participation on a
working group or
committee
• Refining scope
• Identifying clinical
outcomes
• Reviewing protocol
• Making
recommendations
• Process, impact, participant
satisfaction
• Every HTA
NICE, England,
Wales
Quasi-
governmental,
national
• To promote fairness and inclusion
of a range of stakeholders
• To enhance patient or public
support of decisions
• To help ensure decisions reflect
patient and public values
• To enhance patient and public
understanding of HTA
• Participation on a working
group or committee
• Identifying topics
• Refining scope
• Appraising evidence
• Making recommendations
• Disseminating results
• Participation on a
working group or
committee
• Identifying topics
• Refining scope
• Appraising evidence
• Making
recommendations
• Guidance on moral and
ethical issues
• Participant satisfaction
• Every HTA
HAS, France Quasi-
governmental,
national
• To promote fairness and inclusion
of a range of stakeholders
• To enhance patient or public
support of decisions
• To help ensure decisions reflect
patient and public values
• Participation on a working
group or committee
• Refining scope
• Reviewing reports
• Appraising evidence
• Participation on a
working group or
committee
• Refining scope
• Reviewing reports
• Appraising evidence
• Process
• Currently conducting first
evaluation
G-BA, Germany Quasi-
governmental,
national
• To promote fairness and inclusion
of a range of stakeholders
• To help ensure decisions reflect
patient and public values
• Participation on a working
group or committee
• Identifying topics
• Refining scope
• Not applicable • Not currently evaluating PPI
activities
AGENAS, Italy Quasi-
governmental,
national
• To promote capacity building
• To promote fairness and inclusion
of a range of stakeholders
• To help ensure decisions reflect
patient and public values
• To enhance patient and public
understanding of HTA
• Data collection
• Disseminating results
• Identifying topics
• Review reports
• Not currently evaluating PPI
activities
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Table 1. Continued
HTA organization involves
Organization,
country
HTA organization
structure, level
Stated reasons for patient and
public initiatives Patients Members of the public
Type of evaluations conducted;
frequency of evaluation
CEM,
Luxembourg
Department within
government
ministry,
national
• Not applicable • Not applicable • Not applicable • Not currently evaluating PPI
activities
ZiNL,
Netherlands
Quasi-
governmental,
national
• To enhance patient or public
support of decisions
• To help ensure decisions reflect
patient and public values
• Identifying topics
• Refining scope
• Identifying clinical
outcomes
• Appraising evidence
• Not applicable • Participant satisfaction
• Every HTA
ZonMw,
Netherlands
Quasi-
governmental,
national
• To promote fairness and inclusion
of a range of stakeholders
• To help ensure decisions reflect
patient and public values
• Participation on a working
group or committee
• Identifying topics
• Identifying clinical
outcomes
• Reviewing protocol
• Disseminating results
• Participation on a
working group or
committee
• Identifying topics
• Identifying clinical
outcomes
• Reviewing protocol
• Evaluation planning in process
Center of
Healthcare
Quality and
Control,
Romania
Quasi-
governmental,
national
• To enhance patient and public
understanding of HTA
• Participation on a working
group or committee
• Participation on a
working group or
committee
• Not currently evaluating PPI
activities
SBU, Sweden Independent
government
agency, national
• To promote capacity building
• To promote fairness and inclusion
of a range of stakeholders
• To enhance patient or public
support of decisions
• To help ensure decisions reflect
patient and public values
• To enhance patient and public
understanding of HTA
• Participation on a working
group or committee
• Refining scope
• Identifying clinical
outcomes
• Reviewing reports
• Disseminating results
• Not applicable • Non-systematic analysis of
PPI activities completed, with
plans for future structured
evaluation
CDE, Taiwan Quasi-
governmental,
national
• To promote capacity building
• To promote fairness and inclusion
of a range of stakeholders
• To enhance patient or public
support of decisions
• To help ensure decisions reflect
patient and public values
• To enhance patient and public
understanding of HTA
• Participation on a working
group or committee
• Reviewing reports
• Appraising evidence
• Disseminating results
• Participation on a
working group or
committee
• Reviewing reports
• Appraising evidence
• Making
recommendations
• Disseminating results
• Process, impact, participant
satisfaction
• Annually
Clinical
Effectiveness
Group,
Taiwan
Quasi-
governmental,
national
• To promote fairness and inclusion
of a range of stakeholders
• To enhance patient or public
support of decisions
• To help ensure decisions reflect
patient and public values
• Reviewing protocol
• Data collection
• Data analysis
• Reviewing reports
• Disseminating results
• Participation on a
working group or
committee
• Reviewing protocol
• Data analysis
• Reviewing reports
• Not currently evaluating PPI
activities
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Table 1. Continued
HTA organization involves
Organization,
country
HTA organization
structure, level
Stated reasons for patient and
public initiatives Patients Members of the public
Type of evaluations conducted;
frequency of evaluation
AHTAPol,
Poland
Quasi-
governmental,
national
• To promote fairness and inclusion
of a range of stakeholders
• Reviewing reports • Reviewing reports • Not currently evaluating PPI
activities
SMC, Scotland Quasi-
governmental,
national
• To promote capacity building
• To promote fairness and inclusion
of a range of stakeholders
• To enhance patient or public
support of decisions
• To help ensure decisions reflect
patient and public values
• To enhance patient and public
understanding of HTA
• Participation on a working
group or committee
• Writing and reviewing
reports
• Appraising evidence
• Making recommendations
• Disseminating results
• Participation on a
working group or
committee
• Writing and reviewing
reports
• Appraising evidence
• Making
recommendations
• Disseminating results
• Process, impact, participant
satisfaction
• Evaluation as continuous
improvement exercise
AGENAS, Agenzia Nazionale per i servizi sanitari Regionali; AHTAPol, Agency for Health Technology Assessment in Poland; CADTH, Canadian Agency for Drugs and Technology in
Health; CDE, Center for Drug Evaluation; CEM, Cellule d’expertise médicale; G-BA, Gemeinsamer Bundesausschuss; HAS, Haute Autorité de Santé; IETS, Instituto de Evaluación
Tecnológica en Salud; NICE, National Institute for Health and Care Excellence; SBU, Swedish Agency for health technology assessment and assessment of social services; SMC,
Scottish Medicines Consortium; ZiNL, Zorginstituut Nederland; ZonMw, Netherlands Organization for Health and Research Development.
details of when in the HTA process patients and members of
the public are involved.
Eleven respondents (73.3 percent) reported involving both
patients and members of the public in the HTA process or
HTA decision making, while three (20.0 percent) reported in-
volving patients only. One organization (6.7 percent) reported
not involving patients or members of the public and indicated
PPI would be considered in future cases if a commissioned
request required it. Organizations reported involving patients
for a range of activities spanning both HTA processes and
HTA decision making including, in order of the HTA process,
participating in a working group or committee to provide
opinions and perspectives (n = 10; 66.7 percent), identify-
ing topics for assessment (n = 4; 26.7 percent), refining
the scope of assessments (n = 7; 46.7 percent), identifying
clinical outcomes (n = 5; 33.3 percent), reviewing protocols
(n = 3; 20.0 percent), collecting data (n = 3; 20 per-
cent), analyzing data (n = 1; 6.7 percent), writing reports
(n = 1; 6.7 percent), reviewing draft reports (n = 7; 46.7
percent), appraising evidence (n = 5; 33.3 percent), making
recommendations (n = 3; 20.0 percent), and helping to dissem-
inate results (n = 8; 53.3 percent).
Members of the public were similarly reported to partici-
pate across the HTA process, including: participating in a work-
ing group or committee (n= 9; 60.0 percent), identifying topics
for assessment (n = 3; 20.0 percent), refining the scope of as-
sessments (n = 4; 26.7 percent), identifying clinical outcomes
(n= 2; 13.3 percent), reviewing research protocols (n= 3; 20.0
percent), analyzing data (n = 1; 6.7 percent), writing reports (n
= 1; 6.7 percent), reviewing draft reports (n = 7; 46.7 percent),
appraising evidence (n = 4; 26.7 percent), making recommen-
dations (n= 4; 26.7 percent), and helping to disseminate results
(n = 2; 13.3 percent).
Evaluation of Patient and Public Involvement
Types and Frequency of Evaluation Activities. As outlined in Table 1, of the
fourteen respondents who conduct PPI activities, seven orga-
nizations (50.0 percent) responded that they evaluate, or have
evaluated, those activities and two (14.3 percent) reported that
they planned to start the evaluation process for upcoming
HTAs. Of the remaining five organizations, one commented
that they have not conducted any evaluation to date due to a
lack of resources, but otherwise no specific reasons were re-
ported for not evaluating PPI activities.
Of the seven organizations who have conducted some eval-
uation work, three (42.8 percent) reported having conducted
evaluations of participant satisfaction, process evaluations, and
impact evaluations, one (14.3 percent) reported conducting
both process evaluations and impact evaluations, one reported
conducting process evaluations only, and two (28.6 percent) re-
ported conducting evaluations of participant satisfaction only.
The frequency of evaluation varied across the respondents, the
type of evaluation conducted and the type of PPI activity.
Application and Dissemination of Evaluation Results. Five of the seven orga-
nizations who have conducted evaluation work responded to
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an open-ended question about how results of their evaluation
activities are used within their programs. All five commented
that results are used to inform changes to PPI activities with
the overall goal of improving activities. Some examples are to
ensure that patients’ perspectives are captured efficiently and
reliably, identify education and training needs of participants
(e.g., patients, patient groups, HTA staff), identify and address
issues raised by participants in the process, and help to direct
strategic priorities and plan for PPI activities for the upcoming
year. HAS and IETS reported that the results of their evalua-
tion activities, in this case a survey, are summarized and used
to identify any issues or concerns. Relevant feedback is then
generated and used to refine particular processes.
At NICE, evaluation results are used to guide the level
and type of support provided by their Patient Involvement Pro-
gram. At the SMC, continuous evaluation informs annual work
planning for PPI activities under the direction of the PIN Ad-
visory Group. As required, formal recommendations are pre-
pared for the SMC Executive, who to date have enacted all
such recommendations. CADTH commented that in addition to
shaping process change over time, evaluation results have been
used to illustrate the value of PPI activities both internally and
externally.
Four organizations reported how evaluation results are
shared with other organizations, and all four reported sharing
the results at conferences (n = 4; 57.1 percent), three reported
publishing them on their Web site (n= 3; 42.8 percent) and two
reported publishing them in a newsletter (n = 2; 28.6 percent).
Changes Made to Patient and Public Involvement Activities. Five organizations
described specific changes made to their PPI activities as a
result of their evaluations, with varying levels of detail pro-
vided. IETS commented generally that following their evalua-
tion, channels of communication have been improved with pa-
tients gaining access to HTA results at various and appropriate
stages. At HAS, conducting and reflecting on evaluation results
motivated their intention to develop documents to clarify the in-
tent of PPI activities, and guidance and tools to address specific
issues, for example, desirable qualities for a patient represen-
tative and how to encourage participation among patient repre-
sentatives on committees.
SMC identified numerous changes as a result of continu-
ous evaluation, many focused on patient groups. Changes in-
clude streamlining the submission process, providing a doc-
ument that summarizes background information on the tech-
nology under review, increased transparency around conflict
of interest declarations, training and education, standardizing
presentations at committee meetings, and changes to the em-
bargoed decision-making process that gives patient groups ad-
vance warning. In addition, SMCs evaluation work motivated
them to increase public awareness of their HTA activities, de-
velop a proactive approach to identify patient and caregiver rep-
resentatives for each HTA, and establish Patient and Clinician
Engagement mentors.
Past evaluations at NICE (24;25) prompted changes in re-
sponse to a key finding that patient expert members found
committee participation to be daunting. Accordingly, several
changes to committee structure were implemented including
ensuring support is provided before committee meetings, hav-
ing the committee chair personally greet them at meetings
where possible, having a lay member sit next to them and up-
dating the patient expert submission form to improve clarity,
provide guidance on completion, and distinguish forms for pa-
tient organizations and individual patients.
A 2012 evaluation of the patient input process into the
Common Drug Review at CADTH (26) revealed that, at the
time, CADTH’s PPI program was equivalent or more evolved
compared with most other HTA programs and also identified
several gaps. Resultant recommendations included ensuring
that stakeholders are aligned on the purpose, value, and cred-
ibility of incorporating patient input and that CADTH learn
from and apply methods used by their international counter-
parts. Accordingly, CADTH implemented several changes in-
cluding developing information sessions and awareness strate-
gies, hiring a dedicated staff member, holding training sessions,
and developing a process for individual patients and caregivers
to provide input when a patient group does not exist. In ad-
dition, the CADTH Patient Community Liaison Forum was
formed and annual stakeholder sessions were established to bet-
ter understand patient groups’ needs.
Lessons Learned from Evaluation of Patient and Public Involvement Activities
Challenges Faced during the Evaluation Process. Six organizations responded
to an open-ended question about challenges faced during evalu-
ation. Several were identified, with many repeated across orga-
nizations. Identified challenges include achieving stakeholder
buy-in, managing conflicting stakeholder opinions, managing
expectations of patients and caregiver representatives, resis-
tance to change and resource constraints for both the evalua-
tion itself and implementation of any resultant recommenda-
tions. Additionally, variation in HTA processes across differ-
ent programs (e.g., drugs, medical devices, medical procedures,
rapid HTA, health economics) was identified as a challenge
to developing an overall evaluation strategy. A further chal-
lenge results from the variation in the goals for PPI for dif-
ferent stakeholders, for example patient groups, researchers, or
committee members. Each stakeholder group may experience
HTA involvement differently and have different interpretations
of success.
Facilitators to the Evaluation Process. Three respondents (CADTH, NICE,
SMC) identified specific facilitators to evaluation, two which
focused on having sufficient resources to conduct evaluation
activities and implement any recommendations, and the sup-
port of senior leadership to embrace any changes. NICE stated
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that their evaluations work best when patients are involved on
the evaluation team, including patient groups, patient experts
and lay members, for example, to help design a questionnaire,
interpret results, and define recommendations and implemen-
tation plans. Similarly at the SMC, the PIN Advisory Group,
which includes representation from public partners and patient
and caregiver organizations, helps to ensure understanding of
current experiences with SMC processes and advise on im-
provement initiatives that are both feasible and acceptable.
Insights on Evaluation of Patient and Public Involvement Activities. NICE and HAS
shared further insights through an open-ended question on
the evaluation of PPI activities. HAS advocated for sharing
among HTA organizations, for example PPI satisfaction ques-
tionnaires, experienced challenges faced during the evaluation
process and cases where the inclusion of patient perspectives
was helpful. NICE recommended setting explicit objectives
and developing an evaluation process at the same time as PPI
activities are established. They also suggested that patients
and patient groups be involved in designing and executing the
evaluation process and applying the learnings in practice.
Furthermore, NICE recommended that proposed changes be
implemented using a phased approach, so that they remain
manageable, and also managing expectations as to what can be
achieved or changed.
Future Plans for Evaluation of Patient and Public Involvement Activities. Six respon-
dents described their future plans, each indicating an ongoing
commitment to evaluation. At SMC, the PIN Advisory Group
ensures a continuous focus on developing and strengthening
PPI. NICE reported a current and ongoing evaluation of PPI
across the organization (broader that HTA), and CADTH simi-
larly reported a current evaluation as part of a requirement for
formal evaluation every 5 years. In addition, HAS reported a
current initiative to both develop and evaluate a process for PPI
in rapid HTA. Finally, while ZonMW and SBU reported not
having yet conducting formal evaluations, they are currently
planning for future evaluations of their PPI activities.
DISCUSSION
A primary goal of this survey was to identify approaches used
by HTA organizations to evaluate their PPI initiatives, includ-
ing perceived facilitators and barriers to evaluation. We ob-
tained responses from fifteen organizations from twelve coun-
tries, representing a 27.8 percent response rate. Consistent
with the findings of recent reviews (8;11;12), patients (14/15)
and members of the public (10/15) are involved in a wide
range of HTA processes conducted by the organizations in our
sample.
The results reveal that, of the organizations that responded,
evaluation of PPI activities is occurring across a small but di-
verse set. Seven of the responding organizations reported hav-
ing conducted evaluations, including patient satisfaction, pro-
cess evaluation or impact evaluation. These results signal that
HTA organizations are conducting evaluation activities more
broadly than represented in the published literature, which have
focused predominantly on evaluating and describing the im-
pact of PPI (1;2;4;12). Due to our small sample size and low
response rate (27.8 percent), however, the proportion of HTA
organizations that both conduct and evaluate PPI activities re-
mains unclear.
Approaches to evaluating PPI appear to vary widely, from
extensive interviews or document reviews for example to
something more streamlined including regular surveying of
participants. Regardless of the intensity of the strategy, a fo-
cus on evaluation is particularly notable in light of the con-
siderable workload of HTA organizations, with many com-
peting deadlines and finite resources. It is encouraging in
this context to observe priority being given to evaluation
activities, which ultimately aim to enhance efficiency and
effectiveness.
Importantly, many specific changes were outlined by re-
spondents as following from their evaluation activities, which
spanned a wide range of issues. Conducting evaluations and
implementing resultant recommendations appears to have pos-
itively impacted both the experience of participating in HTA
from the perspective of patients and members of the pub-
lic, as well as the quality of patient and caregiver input
into HTA. In specific instances, evaluation activities were
also reported to lead to increased awareness of PPI initia-
tives in HTA, and, therefore, facilitate the proactive recruit-
ment of future participants, and to illustrate the value of
PPI both internally to an HTA organization and externally to
stakeholders.
Through this survey, we were able to elicit insights and per-
spectives on the evaluation process, which should be of value to
those planning this sort of work in the future. Specifically, chal-
lenges noted by the respondents included both general issues
related to the evaluative process (e.g., achieving stakeholder
buy-in, managing conflicting opinions, resistance to change)
and general methodological issues (e.g., how to define success
with wide ranging goals, how to compare PPI in the context of
rapid versus full HTA). Facilitators included provision of ade-
quate resources to both conduct evaluations as well as imple-
ment any recommendations, in addition to the support of se-
nior leadership and participation of patients and members of
the public in the evaluative process. While no respondent ex-
plicitly commented that methodological development needs to
occur, this seems implied in the elements stated as challenging
the evaluation process.
The reported facilitators and challenges with evaluation
of PPI activities in HTA are not unlike those reported in the
broader evaluation literature. A foundation of the evaluation
literature relates to the development and documentation of pro-
gram theories, for example through the use of logic models,
or theories of change. A program theory should outline the
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inputs, activities, outputs and short- and long-term outcomes
intended for a program. A logic model, for example, can help
make explicit the expected relationship between these program
elements (27). Logic models can be useful to help design pro-
grams, facilitate accountability to a stated plan, and also guide
program evaluation. Critical to the development of a program
theory is the involvement of all relevant stakeholders to ensure
buy-in regarding inputs, activities, and program goals in par-
ticular how program goals will be measured to define success.
Stakeholder involvement should persist throughout the evalua-
tion cycle, including data collection, analysis, and the develop-
ment and implementation of recommendations.
Many of these concepts were mentioned implicitly or ex-
plicitly by respondents to our survey, although without refer-
ence to formal program evaluation theory or methods. For ex-
ample, NICE recommended that organizations develop explicit
objectives for PPI at the outset, and ideally also develop an eval-
uation plan at the same time as the PPI activities are established.
NICE also remarked that their evaluations are more productive
when patients or members of the public are part of the eval-
uation team. These reflections speak to the need to plan PPI
programs and evaluation activities simultaneously, and also to
be specific in terms of stated goals and how those goals should
be measured. They also suggest that developing a greater un-
derstanding of evaluation theory and methods could be an im-
portant step forward for organizations engaged in PPI.
Of note, most organizations in our sample reported mul-
tiple reasons for implementing PPI activities. While it is
widely acknowledged that PPI activities are grounded in a
broad set of goals, including enhancing the relevance of as-
sessments, strengthening the evidentiary contribution, comple-
menting clinical and researcher expertise, and enhancing the
openness and inclusiveness of the decision process (1;12), these
broad ranging objectives may complicate evaluation (20), as
each objective would require its own set of anticipated and mea-
sureable outcomes.
First, broad agreement among stakeholders is required re-
garding how to evaluate whether or not often vaguely ar-
ticulated objectives have been achieved. Second, tailored ap-
proaches to collect data against which to measure success for
each distinct objective might be needed. What is important is
that the goals for involving patients and members of the public
are prespecified and measurable, that an evaluation plan gath-
ers data targeted for those goals, and there is consensus among
relevant stakeholders regarding how to define success. The con-
cept of evaluability assessment might also be relevant, as a pre-
cursor to evaluation. Evaluability assessments could be used to
assess and ensure that PPI programs are ready for evaluation,
with sufficient logic or theory to support committed resources
and activities resulting in the achievement of measurable ob-
jectives, and that there is sufficient stakeholder buy-in to both
conduct an evaluation and implement resultant recommenda-
tions (28).
Limitations
The completeness of this survey is limited as it is based on only
fifteen responses from twelve countries, representing seven or-
ganizations who conduct and evaluate PPI activities. While
we cannot be certain of the extent, it is likely that some or-
ganizations who evaluate their PPI activities did not respond
to our questionnaire. Furthermore, the maximum number of
responses received from each organization was two, but in
most cases there was one response per country or organization.
Given the possibility that different PPI or evaluation strategies
are used by different programs or groups within a given country
or organization, there is further reason to believe that our results
do not reflect all experiences with evaluation. While we made
attempts to contact authors to clarify submitted responses, in
the end, we spoke directly to seven of the fifteen respondents.
We, therefore, did not verify reported data from eight repre-
sented HTA organizations, which raises the potential for inac-
curate, or out of date, data especially given the evolving nature
of PPI activities.
Finally, in our questioning relating to evaluation strategies,
we did not specifically ask whether there were any differences
in approach related to evaluating patient involvement as com-
pared to involving members of the public, primarily due to not
wanting to add further questions to an already long question-
naire. It is likely that a broader evaluation of experiences will
expand over the coming years, and we hope this report may
serve to encourage evaluation among those who have not yet
established a process.
CONCLUSIONS
Our survey identified international HTA organizations that have
developed and conducted initiatives to evaluate their PPI activ-
ities. A range of strategies are described that span the evalua-
tion of process, impact and satisfaction, and at varying levels
of time and resource requirements. Few explicit references to
evaluation theory were noted, although respondents appear to
acknowledge established facilitators to program evaluation in-
cluding the need for explicit, measurable objectives and the in-
clusion of a range of stakeholders, including patients and mem-
bers of the public on evaluation teams.
There is a continued interest in the evaluation of PPI activ-
ities through HTAi, and a recently published book (29) focused
on patient involvement in HTA contains a chapter on this topic,
with a proposed evaluation framework. It will be important for
HTA organizations to share their approaches and experiences
with evaluation and perhaps to test this framework.
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